| Project/Area Number |
22501049
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Department of Clinical Research, National Hospital Organization Kagoshima Medical (2013)
Kagoshima University (2010-2012) |
|---|
Principal Investigator |
UOZUMI KIMIHARU 独立行政法人国立病院機構鹿児島医療センター(臨床研究部), 内科, 医長 (90253864)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARIMA Naomichi 鹿児島大学, 大学院医歯学総合研究科, 教授 (30175997)
SUZUKI Shinsuke 鹿児島大学, 大学院医歯学総合研究科, 助教 (20437974)
MATSUSHITA Kakushi 鹿児島大学, 医学部歯学部附属病院, 講師 (00363630)
|
|---|
| Project Period (FY) |
2010-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 成人Ｔ細胞白血病 / 三酸化砒素 / 化学療法 / 成人T細胞白血病 |
|---|
| Research Abstract |
We investigated the efficacy and safety of the new multi-drug combination chemotherapy (As-RCM) using the drug (arsenic trioxide, As) that may eradicate leukemic stem cells of ATL. In this study, the treatment consisted of intravenous As (0.15 mg/kg, day1-5) and combination chemotherapy (RCM therapy) that previously reported. In 2010-2012, seven patients was enrolled. All patients received 3-5 courses mLSG15 treatment. Only 2 patients completed the planned treatment. Of the 7 patients, 2 patients achieved PR, and 5 patients achieved SD-PD. Overall response rate was 28.6%. Adverse events were neutropenia (100%), thrombocytopenia (43%), anemia (29%), and QTc prolongation (100%). All adverse events were manageable.
In conclusion, although the further studies designed to determine a more suitable combination regimen and are necessary, the new multi-drug combination chemotherapy (As-RCM) using arsenic trioxide seems to be effective in the treatment for relapsed and refractory ATL.
|
